Nocturia indicates a poor health status and increases mortality in male patients with type 2 diabetes mellitus

Liu, Huiying; Chung, Min-Shen; Wang, Hung-Jen; Liu, Rue‐Tsuan; Chuang, Yao‐Chi

doi:10.1007/s11255-016-1310-3

Cited by 17 publications

(18 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liu et al [157] investigated the effects of T therapy on LUTS in 632 diabetic men and reported that men with the lowest T levels (2.21±0.51 ng/dL) had the highest prevalence of nocturia, and it was more likely to be severe (≥3 times/night). Francomano et al [126] examined the effects of T therapy for 5 years on LUTS in 20 obese men with TD and Met S and compared the findings in 20 matched subjects who remained untreated.…”

Section: Does Testosterone Therapy Improves Lower Urinary Tract Symptmentioning

confidence: 99%

Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome

Traish

Johansen

2018

World J Mens Health

View full text Add to dashboard Cite

Lower urinary tract function is modulated by neural, vascular and urethral and bladder structural elements. The pathophysiological mechanisms of lower urinary tract symptoms (LUTS) encompass prostate enlargement, alterations in urethra histological structure bladder fibrosis and alterations in pelvic neuronal and vascular networks, The complex pathophysiological relationship between testosterone (T) deficiency (TD) and the constellations LUTS, and metabolic dysfunction manifested in the metabolic syndrome (Met S) remains poorly understood. TD has emerged as one the potential targets by which Met S may contribute to the onset and development as well as worsening of LUTS. Because it has been recognized that treatment of men with Met S with T therapy ameliorates Met S components, it is postulated that T therapy may represent a therapeutic target in improving LUTS. Furthermore, the effect of TD on the prostate remains unclear, and often debatable. It is believed that T exclusively promotes prostate growth, however recent evidence has strongly contradicted this belief. The true relationship between benign prostatic hyperplasia, TD, and LUTS remains elusive and further research will be required to clarify the role of T in both benign prostatic hypertrophy (BPH) and LUTS as a whole. Although there is conflicting evidence about the benefits of T therapy in men with BPH and LUTS, the current body of literature supports the safety of using this therapy in men with enlarged prostate. As the population afflicted with obesity epidemic continues to age, the number of men suffering from Met S and LUTS together is expected to increase.

show abstract

Section: Does Testosterone Therapy Improves Lower Urinary Tract Symptmentioning

confidence: 99%

Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome

Traish

Johansen

2018

World J Mens Health

View full text Add to dashboard Cite

show abstract

“…In patients with type 2 diabetes, depressive symptoms were positively associated with hyperglycemia (20) and poor prognoses (21). Nocturia was positively associated with diabetic retinopathy (22), erectile dysfunction (23) and mortality (24). The assessment of nocturia was easy to make in clinics.…”

Section: Introductionmentioning

confidence: 99%

Nocturia and Prevalence of Depressive Symptoms in Japanese Adult Patients With Type 2 Diabetes Mellitus: The Dogo Study

Furukawa

Sakai

Niiya

et al. 2018

Canadian Journal of Diabetes

View full text Add to dashboard Cite

show abstract

“…As demonstrated by Liu et al in a study of 632 diabetic men, those men with the lowest testosterone levels (2.21±0.51 ng/dL) had the highest prevalence of nocturia, and it was more likely to be severe (≥3 times per night) (71). As expected from the previous discussion, those with severe nocturia had mortality 3 times that of men without severe hypogonadism at 3.5 years follow-up.…”

Section: Nocturiamentioning

confidence: 97%

Testosterone replacement therapy and voiding dysfunction

Baas

Köhler

2016

Transl. Androl. Urol.

View full text Add to dashboard Cite

Testosterone replacement therapy (TRT) represents an increasing popular treatment option for men with late-onset hypogonadism (LOH). Because of unsubstantiated beliefs of testosterone’s effect on the prostate, the FDA has recently placed a warning on testosterone products, stating that TRT may worsen benign prostatic hyperplasia (BPH). Within this review article we have demonstrated the current understanding of the physiology of testosterone and its relationship with prostatic and lower urinary tract physiology. The current evidence suggests that not only does TRT not worsen lower urinary tract symptoms (LUTS), but that hypogonadism itself is an important risk factor for LUTS/BPH.

show abstract

Nocturia indicates a poor health status and increases mortality in male patients with type 2 diabetes mellitus

Abstract: The presence of nocturia was associated with erectile dysfunction, systemic vascular events, higher mortality, and indicated poor health in male with type 2 diabetic mellitus.

Cited by 17 publications

References 23 publications

Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome

Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome

Nocturia and Prevalence of Depressive Symptoms in Japanese Adult Patients With Type 2 Diabetes Mellitus: The Dogo Study

Testosterone replacement therapy and voiding dysfunction

Contact Info

Product

Resources

About